Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Durvalumab (Primary) ; Metformin (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 14 Jan 2019 Status changed from active, no longer recruiting to recruiting.
- 27 Nov 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 16 Aug 2018 New trial record